Clinical Trials Browser

Has results × eribulin × 1 year × Clear all

NCT04345913 2026-05-27

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Phase 1/2 Active not recruiting

24 enrolled 24 charts

Triple Negative Breast Neoplasms

NCT05104866 2026-05-05

A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)

Phase 3 Active not recruiting

732 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03331250 2025-12-23

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Phase 2 Active not recruiting

13 enrolled 9 charts

Hemangiosarcoma, Hemangioendothelioma, Epithelioid

NCT03526679 2025-12-05

LEADER

Phase 1/2 Completed

30 enrolled 9 charts

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT02623972 2025-11-25

A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer

Phase 2 Active not recruiting

22 enrolled 12 charts

Inflammatory Breast Neoplasms

NCT01676818 2025-11-06

Eribulin Mesylate in Treating Patients With Advanced or Recurrent Cervical Cancer

Phase 2 Completed

32 enrolled 17 charts

Uterine Cervical Neoplasms

NCT03734029 2025-10-06

Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]

Phase 3 Active not recruiting

557 enrolled 22 charts 1 FDA

Breast Neoplasms, Neoplasm Metastasis

NCT03899805 2025-08-28

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Phase 2 Completed

57 enrolled 14 charts

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous